Ozierański, Krzysztof (55955787800)Krzysztof (55955787800)OzierańskiTymińska, Agata (55621008700)Agata (55621008700)TymińskaKobylecka, Małgorzata (6507048509)Małgorzata (6507048509)KobyleckaCaforio, Alida L.P. (7005166754)Alida L.P. (7005166754)CaforioŠobić-Šaranović, Dragana (57202567582)Dragana (57202567582)Šobić-ŠaranovićRistić, Arsen D. (7003835406)Arsen D. (7003835406)RistićMaksimović, Ružica (55921156500)Ružica (55921156500)MaksimovićSeferović, Petar M. (6603594879)Petar M. (6603594879)SeferovićMarcolongo, Renzo (57210907868)Renzo (57210907868)MarcolongoKrólicki, Leszek (55915712500)Leszek (55915712500)KrólickiOpolski, Grzegorz (55711952200)Grzegorz (55711952200)OpolskiGrabowski, Marcin (11140740100)Marcin (11140740100)Grabowski2025-06-122025-06-122021https://doi.org/10.1016/j.ijcard.2021.02.068https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102783250&doi=10.1016%2fj.ijcard.2021.02.068&partnerID=40&md5=2b70de7c697dc7f702890ff6d2bd1177https://remedy.med.bg.ac.rs/handle/123456789/4199Aim: Myocarditis is an inflammatory disease associated with increased glucose uptake. The hypothesis of this study assumes that 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) may improve specificity and sensitivity in the diagnosis of myocarditis and referral for endomyocardial biopsy (EMB), adding additional information for post-discharge risk stratification. The aim of the study is to assess the diagnostic and prognostic feasibility of FDG-PET/CT in comparison to cardiac magnetic resonance (CMR) (alone or in combination) in patients with clinically suspected myocarditis undergoing EMB. Methods: Fifty hospitalized patients with clinically suspected myocarditis who meet the inclusion/exclusion criteria will be enrolled in a prospective, observational, multicentre, cohort study (NCT04085718). The primary endpoint is the sensitivity and specificity of FDG-PET/CT imaging in the diagnosis of myocarditis. The main secondary endpoints include correlation of FDG-PET/CT imaging with CMR, echocardiography, and EMB results. The patients will undergo the following evaluations: clinical examination, blood tests (including biomarkers of fibrosis and anti-heart autoantibodies (AHA)), ECG, 24 h Holter ECG, echocardiography, CMR, as well as resting single photon emission computed tomography (SPECT) to assess possible myocardial perfusion defects, cardiac FDG-PET/CT and right ventricular EMB. After 6-months a follow-up visit will be performed (including 24 h Holter ECG, echocardiography and CMR). Investigators evaluating individual studies (CMR, SPECT, FDG-PET/CT and EMB) are to be blinded to the other tests' results. Conclusion: We believe that FDG-PET/CT alone or in combination with CMR may be a useful tool for improving diagnostic accuracy in patients with clinically suspected myocarditis. © 2021 Elsevier B.V.